CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 11/30/23

2023-11-30 09:39:45 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals files for $100M mixed shelf offering - filing For further details see: Cyclacel Pharmaceuticals regains complia...

BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice from The Na...

2023-11-28 17:25:26 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals files for $100M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals For further details see: Cyclacel receives notification of deficiency fr...

BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-complianc...

2023-11-14 10:19:36 ET Cyclacel Pharmaceuticals press release ( NASDAQ: CYCC ): Q3 GAAP EPS of -$0.49 misses by $0.13 . As of September 30, 2023, cash equivalents totaled $5.9 million, compared to $18.3 million as of December 31, 2022. Estimates that its available ...

2023-11-14 09:59:20 ET More on Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Earnings Call Transcript Cyclacel Pharmaceuticals files for $100M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Cyclacel Pharmaceuticals ...

2023-11-13 19:32:06 ET Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President, CEO Paul McBarron - EVP, Finance & COO Mark Kirschbaum - SVP, CMO ...

- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, N.J., Nov. 13, 202...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...